PDCD1 and neoplasm: Pembrolizumab is another PD-1 mAb; it has been radiolabeled with [89Zr] to assess tumor uptake and whole-body biodistribution before treatment with the anti-PD-1 antibody as well as to explore its relationship with patient outcomes [26,27].